Radiation therapy as primary and adjuvant treatment for local and regional melanoma

Cancer Control

Volumn 15, Issue 3, 2008, Pages 233-238

  Berk, Lawrence B ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b TAMPA GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESEARCH; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MELANOMA; METASTASIS; PRACTICE GUIDELINE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; TREATMENT PLANNING;

EID: 49649119481     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480801500306     Document Type: Review

References (48)

1. Rofstad EK. Radiation biology of malignant melanoma. Acta Radiol Oncol. 1986;25(1):1-10.
2. Bentzen SM, Thames HD, Overgaard J. Does variation in the in vitro cellular radiosensitivity explain the shallow clinical dose-control curve for malignant melanoma? Int J Radiat Biol. 1990;57(1):117-126.
3. Schwachöfer JH, Crooijmans RP, van Gasteren JJ, et al. Radiosensitivity of different human tumor cell lines grown as multicellular spheroids determined from growth curves and survival data. Int J Radiat Oncol Biol Phys. 1989;17(5):1015-1020.
4. Rofstad EK, Wahl A, Brustad T. Radiation response of multicellular spheroids initiated from five human melanoma xenograft lines. relationship to the radioresponsiveness in vivo. Br J Radiol. 1986;59(706):1023-1029.
5. West CM, Sandhu RR, Stratford IJ. The radiation response of V79 and human tumour multicellular spheroids: cell survival and growth delay studies. Br J Cancer. 1984;50(2):143-151.
6. Rofstad EK. Fractionation sensitivity (alpha/beta ratio) of human melanoma xenografts. Radiother Oncol. 1994;33(2):133-138.
7. Rofstad EK, Mathiesen B, Galappathi K. Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor. Cancer Res. 2004;64(1):13-18.
8. Rofstad EK. Radiation sensitivity in vitro of primary tumors and metastatic lesions of malignant melanoma. Cancer Res. 1992;52(16):4453-4457.
9. Overgaard J, Overgaard M, Hansen PV, et al. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol. 1986;5(3):183-192.
10. Overgaard J. The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys. 1986;12(6):867-872.
11. Bentzen SM, Overgaard J, Thames HD, et al. Clinical radiobiology of malignant melanoma. Radiother Oncol. 1989;16(3):169-182.
12. Doss LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys. 1982;8(7):1131-1134.
13. Dvorak E, Haas RE, Liebner EJ. Contribution of radiotherapy to the management of malignant melanoma. A ten year experience at the University of Illinois Hospital in Chicago. Neoplasma. 1993;40(6):387-399.
14. Konefal JB, Emami B, Pilepich MV. Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology. 1987;164(3):607-610.
15. Olivier KR, Schild SE, Morris CG, et al. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer. 2007;110(8):1791-1795.
16. Strauss A, Dritschilo A, Nathanson L, et al. Radiation therapy of malignant melanomas: an evaluation of clinically used fractionation schemes. Cancer. 1981;47(6):1262-1266.
17. Burmeister BH, Smithers BM, Poulsen M, et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg. 1995;19(3):369-371.
18. Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys. 1985;11(10):1837-1839.
19. Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 1991;20(3):429-432.
20. Salmi R, Holsti P. Effects of roentgen irradiation on human melanoma metastases in the skin. Acta Oncol. 1987;26(1):37-40.
21. Wada H, Nemoto K, Ogawa Y, et al. A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys. 2004;59(2):495-500.
22. Klausner JM, Gutman M, Rozin RR, et al. Conventional fractionation radiotherapy combined with 5-fluorouracil for metastatic malignant melanoma. Am J Clin Oncol. 1987;10(5):448-450.
23. Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg. 2003;129(8):864-868.
24. Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005;103(2):313-319.
25. Krengli M, Masini L, Kaanders JH, et al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2006;65(3):751-759. Epub 2006 May 2.
26. Hietanen T, Nieminen S, Ekfors T, et al. Elective treatment of regional lymph nodes in malignant melanoma. Strahlentherapie. 1985;161(1):1-4.
27. Chang DT, Amdur RJ, Morris CG, et al. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys. 2006;66(4):1051-1055. Epub 2006 Sep 12.
28. Ang KK, Byers RM, Peters LJ, et al. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma: preliminary results. Arch Otolaryngol Head Neck Surg. 1990;116(2):169-172.
29. Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys. 1994;30(4):795-798.
30. Ballo MT, Bonnen MD, Garden AS, et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer. 2003;97(7):1789-1796.
31. Ballo MT, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am. 2003;83(2):323-342.
32. Bonnen MD, Ballo MT, Myers JN, et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer. 2004;100(2):383-389.
33. Ballo MT, Ross MI, Cormier JN, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006;64(1):106-113. Epub 2005 Sep 22.
34. O'Brien CJ, Petersen-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck. 1997;19(7):589-594.
35. Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma: Trans Tasman Radiation Oncology Group (TROG) study 96.06. Radiother Oncol. 2006;81(2):136-142.
36. Creagan ET, Cupps RE, Ivins JC, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer. 1978;42(5):2206-2210.
37. Ballo MT, Garden AS, Myers JN, et al. Melanoma metastatic to cervical lymph nodes: can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck. 2005;27(8):718-721.
38. Ballo MT, Strom EA, Zagars GK, et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2002;52(4):964-972.
39. Al-Refaie WB, Ross MI. Inguinal lymphadenectomy for malignant melanoma. Oper Tech Gen Surg. 2006;8(2):90-102.
40. Taylor A, Rockall AG, Reznek RH, et al. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(5):1604-1612. Epub 2005 Sep 29.
41. Shih HA, Harisinghani M, Zietman AL, et al. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys. 2005;63(4):1262-1269.
42. Cody HS, III. Axillary dissection for breast cancer. Oper Tech Gen Surg. 2006;8(2):66-80.
43. Dijkema IM, Hofman P, Raaijmakers CP, et al. Loco-regional conformal radiotherapy of the breast: delineation of the regional lymph node clinical target volumes in treatment position. Radiother Oncol. 2004;71(3):287-295.
44. Mansur DB, Kong FM, El Naqa I, et al. CT localization of axillary lymph nodes in relation to the humeral head: significance of arm position for radiation therapy planning. Radiother Oncol. 2005;77(2):191-193. Epub 2005 Nov 3.
45. Madu CN, Quint DJ, Normolle DP, et al. Definition of the supraclavicular and infraclavicular nodes: implications for three-dimensional CT-based conformal radiation therapy. Radiology. 2001;221(2):333-339.
46. Delman KA, Lee JE. Therapeutic neck dissection for melanoma. Oper Tech Gen Surg. 2006;8(2):103-111.
47. Poon I, Fischbein N, Lee N, et al. A population-based atlas and clinical target volume for the head-and-neck lymph nodes. Int J Radiat Oncol Biol Phys. 2004;59(5):1301-1311.
48. Morris KT, Marquez CM, Holland JM, et al. Prevention of local recurrence after surgical debulking of nodal and subcutaneous melanoma deposits by hypofractionated radiation. Ann Surg Oncol. 2000;7(9):680-684.